Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis

Fredrik H. Schjesvold, Paul G. Richardson, Thierry Facon, Adrian Alegre, Andrew Spencer, Artur Jurczyszyn, Kazutaka Sunami, Laurent Frenzel, Chang-Ki Min, Sophie Guillonneau, Peggy L. Lin, Solenn Le-Guennec, Frank Campana, Helgi van de Velde, Samira Bensfia, and Sara Bringhen

Disclosures: FHS: Honoraria – Amgen, Celgene, Janssen, MSD, Novartis, Oncoprotecides, Sanofi, SkyliteDX and Takeda; membership on an entity’s Board of Directors or advisory committees – Amgen, Celgene, Janssen, MSD, Novartis, Oncoprotecides, Sanofi and Takeda. PGR: Research funding – Bristol-Myers Squibb, Celgene, Oncoprotecides and Takeda; honoraria – Celgene, Janssen, Karyopharm, Oncoprotecides, Sanofi and Takeda. TF: Membership on an entity’s Board of Directors or advisory committees – Amgen, Celgene, Janssen, Karyopharm, Oncoprotecides, Roche and Takeda. AA: Honoraria – Amgen, Celgene, Janssen, Sanofi and Takeda; membership on an entity’s Board of Directors or advisory committees – Amgen, Celgene, Janssen, Sanofi and Takeda. AS: Research funding – Amgen, Celgene, Haemalogix, Janssen Servier and Takeda; honoraria – AbbVie, Amgen, Celgene, Haemalogix, Janssen, Sanofi, SecuraBio, Specialised Therapeutics Australia, Servier and Takeda; consultancy – AbbVie, Celgene, Haemalogix, Janssen, Sanofi, SecuraBio, Specialised Therapeutics Australia, Servier and Takeda; Speakers Bureau – Celgene, Janssen and Takeda. AJ: Honoraria – Amgen, Celgene, Janssen-Cilag, Karyopharm and Takeda; membership on an entity’s Board of Directors or advisory committees – Karyopharm. KS: Research funding – AbbVie, Alexion Pharma, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, MSD, Ono Pharmaceutical, Sanofi and Takeda Pharmaceulltical; honoraria – Bristol-Myers Squibb, Celgene, Ono Pharmaceutical and Takeda Pharmaceutical. LF Honoraria – Amgen, Celgene, Janssen-CILAG and Takeda. SBr: Honoraria – Amgen, Bristol-Myers Squibb, Celgene and Janssen; membership on an entity’s Board of Directors or advisory committees – Amgen, Celgene, Janssen and Karyopharm; consultancy – Janssen and Takeda. SG, PLL, SL-G, FC, HvdV and SBe are employed by Sanofi. CKM has no relevant financial relationships to disclose.

Contributions: FC, the funder’s clinical study director, was responsible for the ICARIA-MM study oversight. PGR was a coprimary investigator of this study. FHS, PGR, TF, AA, AS, AJ, KS, LF, CKM and SBr were investigators in the study and contributed to data acquisition. PGR, FC and SL-G designed the study. SG and PLL processed the HRQoL data and performed the analysis. SL-G, FC, HvdV and SBe contributed to the analysis and interpretation of data for the work. All authors revised the work for important intellectual content and assume responsibility for data integrity and the decision to submit this manuscript for publication; had full access to the study data; and edited, and reviewed manuscript drafts, and approved the final version for submission.